Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Shareholder Meeting (August 2023)
14 slides from Amplia Therapeutics's shareholder meeting presentation, Aug 24, 2023
Slide 1: CEO & Managing Director's Presentation to Annual General Meeting
ASX RELEASE 24th Aug 2023 CEO & Managing Director’s Presentation to Annual General Meeting Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to release the CEO & Managing Director’s presentation to the Company’s Annual General Meeting (YE 31 March 20
Slide 2: For personal use only
For personal use only
Slide 3: Disclaimer
For personal use only DISCLAIMER “xmplia The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. This presentation is not a prospectus, product di
Slide 4: Company Snapshot
COMPANY SNAPSHOT Ee CORPORATE ACCENT TRIAL Share Price: 8c Seven sites open - VIC, NSW, QLD For personal use only Valuation: $16m 13 patients dosed - Smooth CEO Phase lb transition lAsmoplia THERAPEUTICS PRECLINICAL CSIRO collaboration - wound healing AMP945 with FOLFIRINOX
Slide 5: Corporate: Use of Funds
For personal use only CORPORATE USE OF FUNDS Patents 4.1% Salaries 16.9% Drug Dev. Costs 61.9% Corporate & BD 171% lAsmplia THERAPEUTICS INCREASED PROFILE ¢ Good publicity on ACCENT trial e Presentations at international scientific and industry conferences ¢ Active in local ecosystem INCREASED BD AC
Slide 6: ACCENT Trial
For personal use only ACCENT TRIAL First patient recruited Ethics approvals Cohort 1 completed Cohort 2 open Cohort 3 opens Cohort 2 completed lAsmoplia THERAPEUTICS Cohort 3 expansion
Slide 7: FAK Inhibition in Cancer
For personal use only FAK INHIBITION IN CANCER “xmplia Cell ¢ Preclinical and clinical evidence of role of FAK Intrinsic in tumour growth, resistance to chemotherapy and radiotherapy, in immuno-modulation and in formation of fibrotic tissue e FAK activity promotes cancer both within cancer cell and
Slide 8: Preclinical Studies with FOLFIRINOX
p RECLINICAL STUDIES with FOLFIRINOX 100. Probability of survival % 0 25 50 75 100 125 150 Days AMP945 treatment for 3 days preceding FOLFIRINOX treatment, on an 14 day cycle lAsmolia THERAPEUTICS Combination benefit demonstrated « AMP945 combines with FOLFIRINOX chemotherapy to improve survival in
Slide 9: AMP945 shows activity equivalent to standard-of-care in IPF model
» PRECLINICAL STUDIES “xmplia AMP945 shows activity equivalent to standard-of-care in IPF model » AMP94S is effective in the industry standard model of IPF in the mouse »« AMP945 reduces lung fibrosis (Ashcroft score) to the same level as current standard-of-care drug nintedanib * No combination eff
Slide 10: Collaboration with CSIRO on formulation for topical delivery
PRECLINICAL STUDIES “xmplia Collaboration with CSIRO on formulation for topical delivery ¢ Collaboration with CSIRO to develop topical formulation of our drugs for potential treatment of wounds and burns ¢ Strong scientific rationale for improved wound healing and reduced scarring with FAK inhibitio
Slide 11: Future Milestones: ACCENT Trial
For personal use only FUTURE MILESTONES “xmplia ACCENT TRIAL e Dose escalation complete Q4 23 + IND filing Q423 REREETEEET e South KoreasitesopenQl24 = ee te wc eee PEEETEAAET ¢ Interim analysis Q2 24 >5/26 responders PRRR Phase 2a (24 patients) => MEN => PEATE EET <6/26 3 months PPARRR 2 months (26
Slide 12: Future Milestones: Preclinical Studies
FUTURE MILESTONES “xmplia PRECLINICAL STUDIES - EXPANDING CLINICAL POTENTIAL AND COMMERCIAL OPPORTUNITIES Data from ovarian Data from final cancer studies IPF studies AMP945 AMP945 2023 For personal use only Preliminary Data from data from wound cancer studies healing studies AMP886 AMP945
Slide 13: Values
For personal use only Values Developing life-changing medicines for people with cancer and fibrotic diseases >To be a world class clinical stage biotechnology company with a pipeline of innovative medicines that improve patients’ lives >To be the definitive partner for translating medical discoverie
Slide 14: For personal use only
For personal use only
Amplia Therapeutics — Shareholder Meeting (August 2023) on 6ix